Cargando…
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative co...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669878/ https://www.ncbi.nlm.nih.gov/pubmed/34917173 http://dx.doi.org/10.1177/17562848211059954 |
_version_ | 1784614868198883328 |
---|---|
author | Peyrin-Biroulet, Laurent Sandborn, William J. Panaccione, Remo Domènech, Eugeni Pouillon, Lieven Siegmund, Britta Danese, Silvio Ghosh, Subrata |
author_facet | Peyrin-Biroulet, Laurent Sandborn, William J. Panaccione, Remo Domènech, Eugeni Pouillon, Lieven Siegmund, Britta Danese, Silvio Ghosh, Subrata |
author_sort | Peyrin-Biroulet, Laurent |
collection | PubMed |
description | In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative colitis and/or Crohn’s disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-α inhibitors, a subset of patients with inflammatory bowel disease either do not respond, experience a loss of response after initial clinical improvement or report intolerance to anti-tumour necrosis factor-α therapy. Optimizing outcomes of these agents may be achieved through earlier intervention, the use of therapeutic drug monitoring and thoughtful switching within class. To complement these approaches, evolving predictive biomarkers may help inform and optimize clinical decision making by identifying patients who might potentially benefit from an alternative treatment strategy. This review will focus on the current use of tumour necrosis factor-α inhibitors in inflammatory bowel disease and the application of personalized medicine to improve future outcomes for all patients. |
format | Online Article Text |
id | pubmed-8669878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86698782021-12-15 Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues Peyrin-Biroulet, Laurent Sandborn, William J. Panaccione, Remo Domènech, Eugeni Pouillon, Lieven Siegmund, Britta Danese, Silvio Ghosh, Subrata Therap Adv Gastroenterol Review In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative colitis and/or Crohn’s disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-α inhibitors, a subset of patients with inflammatory bowel disease either do not respond, experience a loss of response after initial clinical improvement or report intolerance to anti-tumour necrosis factor-α therapy. Optimizing outcomes of these agents may be achieved through earlier intervention, the use of therapeutic drug monitoring and thoughtful switching within class. To complement these approaches, evolving predictive biomarkers may help inform and optimize clinical decision making by identifying patients who might potentially benefit from an alternative treatment strategy. This review will focus on the current use of tumour necrosis factor-α inhibitors in inflammatory bowel disease and the application of personalized medicine to improve future outcomes for all patients. SAGE Publications 2021-12-09 /pmc/articles/PMC8669878/ /pubmed/34917173 http://dx.doi.org/10.1177/17562848211059954 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Peyrin-Biroulet, Laurent Sandborn, William J. Panaccione, Remo Domènech, Eugeni Pouillon, Lieven Siegmund, Britta Danese, Silvio Ghosh, Subrata Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title | Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title_full | Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title_fullStr | Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title_full_unstemmed | Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title_short | Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
title_sort | tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669878/ https://www.ncbi.nlm.nih.gov/pubmed/34917173 http://dx.doi.org/10.1177/17562848211059954 |
work_keys_str_mv | AT peyrinbirouletlaurent tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT sandbornwilliamj tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT panaccioneremo tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT domenecheugeni tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT pouillonlieven tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT siegmundbritta tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT danesesilvio tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues AT ghoshsubrata tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues |